Charcot-Marie-Tooth Disease (CMT)

Table of Contents

1. What is Charcot-Marie-Tooth Disease?
2. Genetics and Subtypes
3. Symptoms and Physical Signs
4. Nerve Conduction and Electrophysiology
5. Diagnosis
6. Management and Rehabilitation
7. Emerging Gene and Molecular Therapies
8. Treatments That Have Failed Trials
9. Prognosis and Quality of Life
10. Research Papers
11. Connections
12. Featured Videos

Back to Table of Contents

What is Charcot-Marie-Tooth Disease?

Charcot-Marie-Tooth disease (CMT) is the most common inherited peripheral neuropathy, affecting approximately 1 in 2,500 people worldwide — roughly 2.6 million people globally. It is named after the three neurologists who first described it in 1886: Jean-Martin Charcot, Pierre Marie (France), and Howard Henry Tooth (UK). Despite its name, CMT does not affect the teeth — the name is purely eponymous.

CMT is a group of genetically diverse hereditary motor and sensory neuropathies (HMSN) caused by mutations in more than 100 different genes affecting the peripheral nervous system. These mutations disrupt either the myelin sheath surrounding peripheral nerve axons (demyelinating forms) or the axons themselves (axonal forms), leading to progressive distal limb weakness and sensory loss. The disease is slowly progressive over decades, rarely life-threatening, but significantly impacts quality of life and mobility.

Back to Table of Contents

Genetics and Subtypes

CMT is classified primarily by inheritance pattern and electrophysiological/pathological findings. Genetic testing has identified more than 100 causative genes.

CMT1 — Demyelinating (Autosomal Dominant)

• CMT1A (most common overall, ~50% of all CMT): caused by a 1.5 Mb duplication on chromosome 17p11.2 encompassing the PMP22 gene (peripheral myelin protein 22). Duplication leads to PMP22 overexpression and dysfunctional myelination. Inheritance: autosomal dominant.
• CMT1B: mutations in MPZ (myelin protein zero), the most abundant compact myelin protein. Clinical range wide — from congenital hypomyelination to late-onset axonal phenotype depending on specific mutation.
• CMT1C: mutations in LITAF/SIMPLE.
• CMT1D: mutations in EGR2 (early growth response 2).
• CMT1E: point mutations in PMP22 (vs. duplication in 1A); can cause more severe disease.
• Nerve conduction velocity (NCV): uniformly slowed, typically <38 m/s in median nerve (normal ≥50 m/s).

CMT2 — Axonal (Autosomal Dominant)

• CMT2A (most common axonal form, ~20% of CMT2): mutations in MFN2 (mitofusin 2), a GTPase regulating mitochondrial fusion. Often more severe than CMT1A, with earlier onset and greater disability.
• CMT2E: mutations in NEFL (neurofilament light chain).
• NCV near-normal (>38 m/s) but reduced compound muscle action potential (CMAP) amplitudes, reflecting axon loss rather than myelin dysfunction.

CMTX — X-linked

• CMTX1 (second most common overall, ~10–15% of CMT): mutations in GJB1 (gap junction protein beta 1, also called connexin 32), expressed in Schwann cells and the liver. Males affected more severely than females (intermediate electrophysiology in females).
• Males: NCV 25–40 m/s (intermediate between CMT1 and CMT2 ranges).

CMT4 — Recessive Demyelinating

• Multiple subtypes (CMT4A through CMT4H) caused by recessive mutations in genes including GDAP1, MTMR2, SH3TC2, NDRG1, EGR2, and PRX.
• Generally more severe than dominant CMT1; often causes significant disability by early adulthood.

Hereditary Neuropathy with Liability to Pressure Palsies (HNPP)

• Caused by PMP22 deletion (one copy deleted vs. duplicated in CMT1A) — the genetic "opposite" of CMT1A.
• Presents with recurrent focal neuropathies at compression sites (carpal tunnel, fibular head) rather than a length-dependent pattern.
• Important to distinguish because nerve compression avoidance is the main management strategy.

Back to Table of Contents

Symptoms and Physical Signs

CMT typically begins in the first or second decade of life, though onset can range from infancy to the sixth decade depending on the genetic subtype. Progression is slow — measured over years and decades.

Foot and Ankle

• Pes cavus (high arches): the most characteristic early sign, caused by intrinsic foot muscle weakness leading to imbalanced muscle pull that raises the arch. Present in the majority of CMT patients.
• Hammer toes: hyperextension of the metatarsophalangeal joint with flexion of the proximal interphalangeal joint, caused by intrinsic foot muscle wasting.
• Bilateral foot drop: weakness of ankle dorsiflexors (tibialis anterior) leads to inability to lift the foot during walking, causing a characteristic high-stepping "steppage gait" to avoid tripping.
• Ankle instability: frequent sprains due to proprioceptive loss and peroneal muscle weakness.

"Inverted Champagne Bottle" Legs

• Progressive distal muscle wasting produces the classic appearance of thin lower legs with relatively preserved upper thigh bulk — resembling an inverted champagne bottle.
• This pattern results from the length-dependent axon/myelin dysfunction: longest nerve fibers are affected first, so distal muscles waste before proximal ones.

Upper Limbs

• Hand intrinsic muscle wasting causing weakness of fine motor tasks (buttoning, writing) in later disease.
• Wrist drop may occur in severe cases.
• Tremor (especially in CMT2A) — sometimes called "Roussy-Lévy syndrome" in older literature.

Sensory Symptoms

• Reduced or absent ankle reflexes (often the first clinical sign).
• Decreased vibration sense and proprioception distally — glove-and-stocking distribution.
• Neuropathic pain and cramps are common but variable across subtypes; neuropathic pain is prominent in MPZ-related CMT1B and some CMT2 subtypes.
• Touch and pinprick sensation usually relatively preserved compared to vibration/proprioception.

Scoliosis and Hip Dysplasia

• Scoliosis occurs in approximately 30–40% of CMT patients due to paraspinal muscle weakness asymmetry.
• Hip dysplasia from pelvic/proximal limb girdle weakness occurs in severe early-onset forms.

Back to Table of Contents

Nerve Conduction and Electrophysiology

Nerve conduction studies (NCS) are essential for classifying CMT type and tracking progression.

• Demyelinating threshold: median motor NCV <38 m/s defines demyelinating CMT (CMT1). Normal is ≥50 m/s; values of 38–50 m/s are intermediate.
• CMT1 pattern: uniformly and diffusely slowed NCV across all nerve segments, reflecting uniform dysmyelination (vs. acquired demyelinating neuropathies like CIDP, which show segmental slowing).
• CMT2 pattern: NCV near-normal or mildly slowed, but CMAP amplitudes markedly reduced — reflects axon loss with relatively intact remaining myelin.
• CMTX1 intermediate pattern: NCV 25–40 m/s in males; females often intermediate (30–45 m/s) rather than clearly demyelinating.
• Absent sural nerve action potential: an early and sensitive finding in most CMT types.
• Nerve biopsy: rarely needed for diagnosis but shows "onion bulb" formations in demyelinating CMT (repeated cycles of demyelination and remyelination create concentric Schwann cell processes around axons).

Back to Table of Contents

Diagnosis

Diagnosis combines clinical assessment, nerve conduction studies, family history, and genetic testing.

• Clinical history: slowly progressive distal weakness and wasting, onset in childhood/adolescence, family history (though de novo mutations and recessive forms occur).
• Neurological examination: assess distal weakness, reflexes, vibration sense, proprioception, foot deformities, gait.
• Nerve conduction studies and EMG: classify as demyelinating, axonal, or intermediate; quantify severity.
• Genetic testing: begin with PMP22 duplication (CMT1A) and GJB1 (CMTX1) as they account for ~60–65% of all CMT. Next-generation sequencing (NGS) gene panel for unresolved cases after initial testing.
• Inheritance pattern: autosomal dominant (most CMT1 and CMT2), X-linked (CMTX), autosomal recessive (CMT4) — affects both family counseling and gene panel selection.
• Skin punch biopsy: can assess intraepidermal nerve fiber density; useful when NCS are equivocal.
• High-resolution nerve ultrasound: cross-sectional area of peripheral nerves is diffusely enlarged in CMT1 — useful adjunct when genetic testing is unavailable.
• Exclude acquired neuropathies: CIDP, diabetes, toxic neuropathies, B12 deficiency — particularly when family history is absent.

Back to Table of Contents

Management and Rehabilitation

There is currently no approved disease-modifying pharmacological treatment for any form of CMT. Management is entirely supportive and rehabilitative, but can significantly improve function and quality of life.

Physical Therapy

• Strengthening exercises for proximal and still-functional muscles delay functional decline.
• Balance and proprioceptive training reduces fall risk — falls and fall-related fractures are a major CMT morbidity.
• Stretching of Achilles tendon and plantar fascia to maintain ankle range of motion.
• Aquatic therapy and cycling are well-tolerated and allow aerobic conditioning without high joint impact.

Orthotics and Assistive Devices

• Ankle-foot orthoses (AFOs): the most important functional aid — corrects foot drop and stabilizes the ankle, dramatically reducing tripping and fatigue with ambulation. Custom AFOs are preferred over off-the-shelf for CMT patients with complex foot deformities.
• Footwear modification: high-top shoes provide additional ankle support; rocker-bottom soles reduce forefoot pressure in pes cavus.
• Canes, walkers, wheelchairs: reserved for advanced disease or during acute deterioration.
• Upper extremity splints: wrist stabilizers for impaired grip; built-up handles on utensils and tools.

Orthopedic Surgery

• Foot correction surgery (plantar fascia release, osteotomies, tendon transfers) indicated for painful rigid pes cavus not amenable to orthotics — typically deferred until foot deformity is fixed.
• Scoliosis surgery for severe progressive curves (>40–50°).
• Surgery does not address the underlying neuropathy and is purely mechanical correction.

Pain Management

• Neuropathic pain treated with gabapentin, pregabalin, duloxetine, or tricyclic antidepressants (as for other peripheral neuropathies).
• Cramps responded to stretching and sometimes to magnesium or mexiletine in small series.
• Avoid neurotoxic drugs: vincristine, taxanes, and certain other chemotherapy agents can precipitate severe irreversible neuropathy in CMT patients (PMID: 12663416). Always inform oncologists and surgeons of CMT diagnosis before any neurotoxic procedure.

Back to Table of Contents

Emerging Gene and Molecular Therapies

The exact genetic characterization of CMT has made it an attractive target for precision medicine, and multiple therapeutic strategies are in clinical or preclinical development.

CMT1A Gene Therapy Approaches

• PMP22 gene silencing: since CMT1A is caused by PMP22 overexpression (3 copies instead of 2), the therapeutic goal is to reduce PMP22 mRNA levels. Approaches include antisense oligonucleotides (ASOs) and RNA interference (siRNA/shRNA). PXT3003 (a combination of baclofen, naltrexone, and sorbitol) was an early attempt to reduce PMP22 expression — failed Phase 3 trials.
• AAV-mediated gene therapy: intrathecal delivery of AAV vectors carrying PMP22-targeting shRNA has shown efficacy in rodent models of CMT1A; early-phase trials are in development as of 2024.
• HDAC inhibitors: hypothesized to reduce PMP22 expression via epigenetic mechanisms; no conclusive Phase 2 evidence to date.

CMT2A Approaches

• Mitofusin activators (designed to stabilize MFN2 protein conformation and restore mitochondrial fusion) showed preclinical efficacy in CMT2A mouse models (PMID: 31150291); Phase 1 trials under exploration.

CMTX1 Approaches

• AAV delivery of functional GJB1 (connexin 32) cDNA to Schwann cells via intrathecal injection; early-phase human trials initiated.

Biomarkers for Trial Endpoints

• Neurofilament light chain (NfL): serum NfL is elevated in active axonal degeneration and is being evaluated as a biomarker for disease progression and treatment response in CMT2 trials.
• CMT Pediatric Scale (CMTPedS) and CMT Neuropathy Score version 2 (CMTNSv2): validated clinical outcome measures used as primary endpoints in CMT trials.

Back to Table of Contents

Treatments That Have Failed Trials

Several treatments based on sound biological hypotheses have failed to show benefit in Phase 2/3 CMT clinical trials — an important reminder that rodent model results do not always translate to humans.

• Ascorbic acid (Vitamin C) — CMT1A: rodent studies showed high-dose ascorbic acid reduced PMP22 overexpression and improved motor performance. Four randomized controlled trials in human CMT1A patients failed to demonstrate significant clinical benefit (PMID: 20609441). Ascorbic acid is not recommended for CMT1A.
• PXT3003 (baclofen/naltrexone/sorbitol) — CMT1A: Phase 2 showed dose-dependent improvement; Phase 3 trial failed to meet primary endpoints.
• Curcumin — CMT1B: reduced mutant MPZ aggregation in mice but no human trial results available.
• NT-3 (neurotrophin-3): improved motor function in transgenic CMT1A mice; a small pilot trial in humans showed possible benefit but larger confirmatory trials were not completed.

Back to Table of Contents

Prognosis and Quality of Life

CMT is slowly progressive over decades. Life expectancy is normal in most forms; the disease is rarely if ever directly fatal. Functional prognosis varies considerably by genetic subtype.

• CMT1A: most patients remain ambulatory throughout life, though many require AFOs by age 40–50. A minority (approximately 5–10%) become wheelchair-dependent.
• CMT2A: more severe — a significant proportion of CMT2A patients with early onset (<10 years) require wheelchair use by early adulthood.
• CMT4 recessive forms: often more severe with earlier wheelchair dependence than dominant forms.
• Pain, fatigue, and psychological impact (anxiety, depression) are major quality-of-life determinants independent of motor disability.
• Pregnancy: symptoms may temporarily worsen during the third trimester, typically returning to pre-pregnancy baseline after delivery.
• Genetic counseling: essential for all patients — risk to children depends entirely on the specific CMT gene and inheritance pattern. CMT1A dominant: 50% per pregnancy. CMT4 recessive: 25% per pregnancy if both parents are carriers.
• CMT-specific registries and patient organizations (Charcot-Marie-Tooth Association, CMTA) connect patients to clinical trials and specialized care centers.

Back to Table of Contents

Research Papers

Curated PubMed topic searches and direct PMID links on Charcot-Marie-Tooth disease.

1. Vincristine neuropathy in CMT patients (PMID 12663416)
2. Ascorbic acid trials in CMT1A — failed to show benefit (PMID 20609441)
3. Mitofusin activators in CMT2A mouse model (PMID 31150291)
4. PubMed: PMP22 duplication CMT1A genetics
5. PubMed: CMT nerve conduction velocity classification
6. PubMed: CMT2A MFN2 mitofusin mutations
7. PubMed: CMTX1 GJB1 connexin 32
8. PubMed: Ankle-foot orthosis CMT gait outcomes
9. PubMed: Pes cavus foot deformity hereditary neuropathy
10. PubMed: AAV gene therapy CMT1A PMP22
11. PubMed: CMT neuropathy score clinical trial outcome
12. PubMed: CMT quality of life review

Back to Table of Contents

Connections

• Peripheral Neuropathy
• Guillain-Barré Syndrome
• ALS
• Multiple Sclerosis
• Neuromyelitis Optica (NMOSD)
• Myasthenia Gravis
• Cerebellar Ataxia
• Essential Tremor
• Parkinson's Disease
• Chronic Fatigue Syndrome (ME/CFS)
• Chronic Pain
• Vitamin B12
• Vitamin D3
• Magnesium
• Acetyl-L-Carnitine
• Fatigue
• Depression
• POTS

Back to Table of Contents

×

Featured Videos